Stanley Laman Group Ltd. reduced its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 13.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 51,003 shares of the company's stock after selling 7,846 shares during the period. Stanley Laman Group Ltd.'s holdings in AstraZeneca were worth $3,564,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Brighton Jones LLC grew its position in shares of AstraZeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock valued at $379,000 after purchasing an additional 2,789 shares during the period. GAMMA Investing LLC increased its stake in shares of AstraZeneca by 43.3% during the 1st quarter. GAMMA Investing LLC now owns 7,878 shares of the company's stock valued at $579,000 after acquiring an additional 2,380 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of AstraZeneca by 1.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 311,600 shares of the company's stock worth $22,903,000 after acquiring an additional 5,557 shares during the period. CWA Asset Management Group LLC acquired a new stake in shares of AstraZeneca in the first quarter worth approximately $221,000. Finally, Johnson Investment Counsel Inc. grew its holdings in AstraZeneca by 4.4% in the first quarter. Johnson Investment Counsel Inc. now owns 9,907 shares of the company's stock valued at $728,000 after purchasing an additional 414 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a "hold" rating to a "sell" rating in a research note on Thursday. Weiss Ratings reiterated a "buy (b)" rating on shares of AstraZeneca in a report on Wednesday, October 8th. Finally, Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday, July 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $86.00.
Read Our Latest Analysis on AstraZeneca
AstraZeneca Stock Up 1.0%
Shares of NASDAQ AZN opened at $84.69 on Friday. The stock has a fifty day moving average price of $80.23 and a 200 day moving average price of $73.85. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $86.57. The company has a market cap of $262.66 billion, a P/E ratio of 31.84, a P/E/G ratio of 1.54 and a beta of 0.36.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. The company had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company's revenue was up 16.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.24 earnings per share. Research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
AstraZeneca Cuts Dividend
The company also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were given a dividend of $0.505 per share. This represents a dividend yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca's payout ratio is presently 37.97%.
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
